Gadot Harel 4
4 · Microbot Medical Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Microbot Medical CEO Gadot Harel Receives 480,000-Share Award
What Happened
Gadot Harel, Chairman, President and CEO of Microbot Medical, was granted a derivative award covering 480,000 shares on Feb 18, 2026. The grant is reported at $0.00 per share (total reported value $0) and is described as an option under the company's 2020 Omnibus Performance Award Plan, as amended.
Key Details
- Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (timely within the 2-business-day window).
- Transaction type/code: A (Grant/Award) — derivative award of 480,000 options.
- Price reported: $0.00 per share; total reported purchase value $0.
- Vesting (per footnote): 25% vests and becomes exercisable on Aug 18, 2026; remaining 75% vests equally on a quarterly basis over the following 30 months, subject to acceleration or forfeiture under the Plan.
- Shares owned after transaction: not disclosed in the provided filing excerpt.
- No 10b5-1 plan, tax-withholding sale, or immediate sale of shares is indicated in this filing.
Context
This was an option grant (a derivative award), not an open-market purchase or sale — meaning no shares were sold or bought on the market at the time of grant. Options vest over time, so any potential ownership or sale would depend on future vesting and exercise. Such grants are commonly used for executive compensation and retention; the filing itself does not indicate the insider’s trading intent.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-18+480,000→ 480,000 totalExercise: $2.10Exp: 2036-02-18→ Common Stock, par value $0.01 per share (480,000 underlying)
Footnotes (1)
- [F1]The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.